Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 2 (January 10), 2005: pp. 254-266
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.09.112

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dannenberg, A. J.
Right arrow Articles by DuBois, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dannenberg, A. J.
Right arrow Articles by DuBois, R. N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention

Andrew J. Dannenberg, Scott M. Lippman, Jason R. Mann, Kotha Subbaramaiah, Raymond N. DuBois

From the Department of Medicine, Weill Medical College of Cornell University, New York, NY; Departments of Clinical Cancer Prevention and Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Departments of Medicine, Cancer Biology, and Cell & Developmental Biology, Vanderbilt University Medical Center and the Vanderbilt-Ingram Cancer Center, Nashville, TN

Address reprint requests to Raymond N. DuBois, MD, PhD, Vanderbilt-Ingram Cancer Center, 691 Preston Research Building, 2300 Pierce Avenue, Nashville, TN 37232-6838; e-mail: raymond.dubois{at}vanderbilt.edu.

Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.

Supported by the United States Public Health Service Grants RO1-DK-62112, R01-CA82578, R01-89578, PO1-CA77839 and P01-CA106451. A.J.D. is the Henry R. Erle, M.D.-Roberts Family Professor of Medicine. R.N.D. is the Hortense B. Ingram Professor of Molecular Oncology and the recipient of a National Institutes of Health MERIT award (R37-DK47297).

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Therapeutic Advances in Medical OncologyHome page
D.G. Power and D.H. Ilson
Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers
Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 145 - 165.
[Abstract] [PDF]


Home page
Cancer Prevention ResearchHome page
Role of Cyclooxygenase-2 in Tumor Progression and Survival of Head and Neck Squamous Cell Carcinoma
Cancer Prevention Research, September 1, 2009; 2(9): 823 - 829.



Home page
Mol Cancer ResHome page
Y. M. Kim, S.-Y. Park, and H. Pyo
Cyclooxygenase-2 (COX-2) Negatively Regulates Expression of Epidermal Growth Factor Receptor and Causes Resistance to Gefitinib in COX-2-Overexpressing Cancer Cells
Mol. Cancer Res., August 1, 2009; 7(8): 1367 - 1377.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
C. Berasain, M. J. Perugorria, M. U. Latasa, J. Castillo, S. Goni, M. Santamaria, J. Prieto, and M. A. Avila
The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer
Experimental Biology and Medicine, July 1, 2009; 234(7): 713 - 725.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
C. Husvik, C. Khuu, M. Bryne, and T.S. Halstensen
PGE2 Production in Oral Cancer Cell Lines is COX-2-dependent
Journal of Dental Research, February 1, 2009; 88(2): 164 - 169.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung
Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
Clin. Cancer Res., January 15, 2009; 15(2): 425 - 430.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
R. Czerninski, P. Amornphimoltham, V. Patel, A. A. Molinolo, and J. S. Gutkind
Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model
Cancer Prevention Research, January 1, 2009; 2(1): 27 - 36.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Subbaramaiah, R. Benezra, C. Hudis, and A. J. Dannenberg
Cyclooxygenase-2-derived Prostaglandin E2 Stimulates Id-1 Transcription
J. Biol. Chem., December 5, 2008; 283(49): 33955 - 33968.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
W. Zhang, N. Bhola, S. Kalyankrishna, W. Gooding, J. Hunt, R. Seethala, J. R. Grandis, and J. M. Siegfried
Kinin B2 Receptor Mediates Induction of Cyclooxygenase-2 and Is Overexpressed in Head and Neck Squamous Cell Carcinomas
Mol. Cancer Res., December 1, 2008; 6(12): 1946 - 1956.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Lurje, F. Nagashima, W. Zhang, D. Yang, H. M. Chang, M. A. Gordon, A. El-Khoueiry, H. Husain, P. M. Wilson, R. D. Ladner, et al.
Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab
Clin. Cancer Res., December 1, 2008; 14(23): 7884 - 7895.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Anand, A. B. Kunnumakkara, K. B. Harikumar, K. S. Ahn, V. Badmaev, and B. B. Aggarwal
Modification of Cysteine Residue in p65 Subunit of Nuclear Factor-{kappa}B (NF-{kappa}B) by Picroliv Suppresses NF-{kappa}B-Regulated Gene Products and Potentiates Apoptosis
Cancer Res., November 1, 2008; 68(21): 8861 - 8870.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L. R. Howe and S. M. Lippman
Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs
J Natl Cancer Inst, October 15, 2008; 100(20): 1420 - 1423.
[Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
L. J. Wirth, J. F. Krane, Y. Li, M. Othus, A. E. Moran, D. M. Dorfman, C. M. Norris Jr, L. Goguen, M. R. Posner, R. I. Haddad, et al.
A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions
Cancer Prevention Research, October 1, 2008; 1(5): 339 - 348.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
P. H. Brown, K. Subbaramaiah, A. P. Salmon, R. Baker, R. A. Newman, P. Yang, X. K. Zhou, R. P. Bissonnette, A. J. Dannenberg, and L. R. Howe
Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor-Selective Retinoid
Cancer Prevention Research, August 1, 2008; 1(3): 208 - 214.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. Wang, R. R. Seethala, Q. Zhang, W. Gooding, C. van Waes, H. Hasegawa, and R. L. Ferris
Autocrine and Paracrine Chemokine Receptor 7 Activation in Head and Neck Cancer: Implications for Therapy
J Natl Cancer Inst, April 2, 2008; 100(7): 502 - 512.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
S. A. Grossman, J. Olson, T. Batchelor, D. Peereboom, G. Lesser, S. Desideri, X. Ye, T. Hammour, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma
Neuro-oncol, April 1, 2008; 10(2): 190 - 198.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. W. Visscher, V. S. Pankratz, M. Santisteban, C. Reynolds, A. Ristimaki, R. A. Vierkant, W. L. Lingle, M. H. Frost, and L. C. Hartmann
Association Between Cyclooxygenase-2 Expression in Atypical Hyperplasia and Risk of Breast Cancer
J Natl Cancer Inst, March 19, 2008; 100(6): 421 - 427.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
L C Huber, P Kunzler, S H Boyce, B A Michel, R E Gay, B S Ink, and S Gay
Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts
Ann Rheum Dis, March 1, 2008; 67(3): 389 - 394.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
S. Choi and J.N. Myers
Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy
Journal of Dental Research, January 1, 2008; 87(1): 14 - 32.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
D. Zhang, J. Li, L. Song, W. Ouyang, J. Gao, and C. Huang
A JNK1/AP-1-Dependent, COX-2 Induction Is Implicated in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Cell Transformation through Regulating Cell Cycle Progression
Mol. Cancer Res., January 1, 2008; 6(1): 165 - 174.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. F.G. de Maat, C. J.H. van de Velde, N. Umetani, P. de Heer, H. Putter, A. Q. van Hoesel, G. A. Meijer, N. C. van Grieken, P. J.K. Kuppen, A. J. Bilchik, et al.
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
J. Clin. Oncol., November 1, 2007; 25(31): 4887 - 4894.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. A. Narayanan, B. S. Reddy, M. C. Bosland, D. Nargi, L. Horton, C. Randolph, and N. K. Narayanan
Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence
Clin. Cancer Res., October 1, 2007; 13(19): 5965 - 5973.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell
The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention
Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. S. Choe, Z. Chen, C. M. Klass, X. Zhang, and D. M. Shin
Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., May 15, 2007; 13(10): 3015 - 3023.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D. Zhang, J. Li, K. Wu, W. Ouyang, J. Ding, Z.-g. Liu, M. Costa, and C. Huang
JNK1, but not JNK2, is required for COX-2 induction by nickel compounds
Carcinogenesis, April 1, 2007; 28(4): 883 - 891.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
A. T. Chan, J. E. Manson, D. Feskanich, M. J. Stampfer, G. A. Colditz, and C. S. Fuchs
Long-term Aspirin Use and Mortality in Women
Arch Intern Med, March 26, 2007; 167(6): 562 - 572.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. M. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, F. S. Pasha, M. Saleem, and H. Mukhtar
Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo
Clin. Cancer Res., March 1, 2007; 13(5): 1611 - 1619.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Ponthan, M. Wickstrom, H. Gleissman, O. M. Fuskevag, L. Segerstrom, B. Sveinbjornsson, C. P.F. Redfern, S. Eksborg, P. Kogner, and J. I. Johnsen
Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
Clin. Cancer Res., February 1, 2007; 13(3): 1036 - 1044.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Ding, X. Zhang, J. Li, L. Song, W. Ouyang, D. Zhang, C. Xue, M. Costa, J. A. Melendez, and C. Huang
Nickel Compounds Render Anti-apoptotic Effect to Human Bronchial Epithelial Beas-2B Cells by Induction of Cyclooxygenase-2 through an IKKbeta/p65-dependent and IKK{alpha}- and p50-independent Pathway
J. Biol. Chem., December 22, 2006; 281(51): 39022 - 39032.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Lilenbaum, M. A. Socinski, N. K. Altorki, L. L. Hart, R. S. Keresztes, S. Hariharan, M. E. Morrison, R. Fayyad, and P. Bonomi
Randomized Phase II Trial of Docetaxel/Irinotecan and Gemcitabine/Irinotecan With or Without Celecoxib in the Second-Line Treatment of Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 20, 2006; 24(30): 4825 - 4832.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
J. A. Landolfi and K. A. Terio
Transitional Cell Carcinoma in Fishing Cats (Prionailurus viverrinus): Pathology and Expression of Cyclooxygenase-1, -2, and p53.
Vet. Pathol., September 1, 2006; 43(5): 674 - 681.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Ding, J. Li, C. Xue, K. Wu, W. Ouyang, D. Zhang, Y. Yan, and C. Huang
Cyclooxygenase-2 Induction by Arsenite Is through a Nuclear Factor of Activated T-cell-dependent Pathway and Plays an Antiapoptotic Role in Beas-2B Cells
J. Biol. Chem., August 25, 2006; 281(34): 24405 - 24413.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. D. Basu, T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO
J. Immunol., August 15, 2006; 177(4): 2391 - 2402.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Park, H. J. Jun, M. J. Cho, K. H. Cho, J. S. Lee, J. I. Zo, and H. Pyo
Radiosensitivity Enhancement by Combined Treatment of Celecoxib and Gefitinib on Human Lung Cancer Cells.
Clin. Cancer Res., August 15, 2006; 12(16): 4989 - 4999.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. M. Carothers, A. E. Moran, N. L. Cho, M. Redston, and M. M. Bertagnolli
Changes in Antitumor Response in C57BL/6J-Min/+ Mice during Long-term Administration of a Selective Cyclooxygenase-2 Inhibitor.
Cancer Res., June 15, 2006; 66(12): 6432 - 6438.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. L. Reckamp, K. Krysan, J. D. Morrow, G. L. Milne, R. A. Newman, C. Tucker, R. M. Elashoff, S. M. Dubinett, and R. A. Figlin
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3381 - 3388.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. S. Reddy, C. X. Wang, A.-N. Kong, T. O. Khor, X. Zheng, V. E. Steele, L. Kopelovich, and C. V. Rao
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats.
Cancer Res., April 15, 2006; 66(8): 4542 - 4546.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Huh, A. Liepins, J. Zielonka, C. Andrekopoulos, B. Kalyanaraman, and A. Sorokin
Cyclooxygenase 2 Rescues LNCaP Prostate Cancer Cells from Sanguinarine-Induced Apoptosis by a Mechanism Involving Inhibition of Nitric Oxide Synthase Activity.
Cancer Res., April 1, 2006; 66(7): 3726 - 3736.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. Miller, V. A. Patel, and A. Sorokin
Cyclooxygenase-2 Rescues Rat Mesangial Cells from Apoptosis Induced by Adriamycin via Upregulation of Multidrug Resistance Protein 1 (P-Glycoprotein)
J. Am. Soc. Nephrol., April 1, 2006; 17(4): 977 - 985.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. M. Lippman and J. J. Lee
Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
Cancer Res., March 15, 2006; 66(6): 2893 - 2903.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Mimori, H. Ishii, H. Nagahara, T. Sudo, K. Yamashita, H. Inoue, G. F. Barnard, and M. Mori
FHIT Is Up-Regulated by Inflammatory Stimuli and Inhibits Prostaglandin E2-Mediated Cancer Progression.
Cancer Res., March 1, 2006; 66(5): 2683 - 2690.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Thiel, M. Heinonen, J. Rintahaka, T. Hallikainen, A. Hemmes, D. A. Dixon, C. Haglund, and A. Ristimaki
Expression of Cyclooxygenase-2 Is Regulated by Glycogen Synthase Kinase-3beta in Gastric Cancer Cells
J. Biol. Chem., February 24, 2006; 281(8): 4564 - 4569.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. R. Holla, J. R. Mann, Q. Shi, and R. N. DuBois
Prostaglandin E2 Regulates the Nuclear Receptor NR4A2 in Colorectal Cancer
J. Biol. Chem., February 3, 2006; 281(5): 2676 - 2682.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Chong and D. Cunningham
Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
W. Wu, R. A. Silbajoris, Y. E. Whang, L. M. Graves, P. A. Bromberg, and J. M. Samet
p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression
Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L883 - L889.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. M. Peek Jr., S. Mohla, and R. N. DuBois
Inflammation in the Genesis and Perpetuation of Cancer: Summary and Recommendations from a National Cancer Institute-Sponsored Meeting
Cancer Res., October 1, 2005; 65(19): 8583 - 8586.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. J. Wirth, R. I. Haddad, N. I. Lindeman, X. Zhao, J. C. Lee, V. A. Joshi, C. M. Norris Jr, and M. R. Posner
Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., October 1, 2005; 23(28): 6976 - 6981.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. C. Zatelli, A. Luchin, D. Piccin, F. Tagliati, A. Bottoni, C. Vignali, M. Bondanelli, and E. C. degli Uberti
Cyclooxygenase-2 Inhibitors Reverse Chemoresistance Phenotype in Medullary Thyroid Carcinoma by a Permeability Glycoprotein-Mediated Mechanism
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5754 - 5760.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ogino, J. A. Meyerhardt, M. Cantor, M. Brahmandam, J. W. Clark, C. Namgyal, T. Kawasaki, K. Kinsella, A. L. Michelini, P. C. Enzinger, et al.
Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
Clin. Cancer Res., September 15, 2005; 11(18): 6650 - 6656.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. S. Reddy, J. M. Patlolla, B. Simi, S.H. Wang, and C. V. Rao
Prevention of Colon Cancer by Low Doses of Celecoxib, a Cyclooxygenase Inhibitor, Administered in Diet Rich in {omega}-3 Polyunsaturated Fatty Acids
Cancer Res., September 1, 2005; 65(17): 8022 - 8027.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. S. Choe, X. Zhang, H. J. C. Shin, D. M. Shin, and Z. Chen
Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer
Mol. Cancer Ther., September 1, 2005; 4(9): 1448 - 1455.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. M. Lippman, N. Gibson, K. Subbaramaiah, and A. J. Dannenberg
Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways
Clin. Cancer Res., September 1, 2005; 11(17): 6097 - 6099.
[Full Text] [PDF]


Home page
The OncologistHome page
W. P. Tew, D. P. Kelsen, and D. H. Ilson
Targeted Therapies for Esophageal Cancer
Oncologist, September 1, 2005; 10(8): 590 - 601.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Du, N. K. Altorki, L. Kopelovich, K. Subbaramaiah, and A. J. Dannenberg
Tobacco Smoke Stimulates the Transcription of Amphiregulin in Human Oral Epithelial Cells: Evidence of a Cyclic AMP-Responsive Element Binding Protein-Dependent Mechanism
Cancer Res., July 1, 2005; 65(13): 5982 - 5988.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. G. Banerjee, I. Bhattacharyya, and J. K. Vishwanatha
Identification of genes and molecular pathways involved in the progression of premalignant oral epithelia
Mol. Cancer Ther., June 1, 2005; 4(6): 865 - 875.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. M. Lippman, J. Sudbo, and W. K. Hong
Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development
J. Clin. Oncol., January 10, 2005; 23(2): 346 - 356.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online